Variants of Uncertain Significance (VUS), Explained
A VUS is a genetic change that sits between clearly harmless and clearly harmful — its meaning is not yet known. Understanding why these results occur, and how they get resolved over time, is one of the most reassuring things a patient can learn after panel testing.
Hereditary Cancer Genetics
What a variant of uncertain significance actually is
When a laboratory sequences a gene, it compares the patient's DNA against a reference and flags every place the two differ. Each difference is a variant. Most variants are harmless background diversity; a smaller number meaningfully disrupt how a gene works. Laboratories sort variants into five tiers — benign, likely benign, uncertain, likely pathogenic, and pathogenic.
A variant of uncertain significance (VUS) is the middle tier: a change the lab has observed but cannot yet confidently place as either harmless or disease-causing. It is not a diagnosis, and it is not evidence of disease. It is an honest statement that the available data are insufficient to call the variant either way. A VUS is common — multi-gene panels examine many genes at once, so the chance of encountering at least one uncertain finding rises simply because more DNA is being read.
A VUS is usually not actionable on its own
Professional guidelines are consistent on this point: a VUS should generally not change medical management. Care decisions — additional screening, risk-reducing surgery, or changes to treatment — are based on variants classified as pathogenic or likely pathogenic, together with personal and family history. Acting on an uncertain result risks intervening on a change that later proves to be benign.
For most patients this is the reassuring part: an uncertain result is typically managed by following the same screening recommendations that fit a person's family history, and by waiting for the variant's classification to be refined. The exception is family history itself — if relatives have the same cancers, that history continues to guide care regardless of how a single variant is currently labeled.
How a variant gets reclassified over time
Classification is not permanent. As evidence accumulates, laboratories revisit uncertain variants and move them toward a benign or pathogenic call. Most VUS findings are eventually reclassified as benign.
Population frequency data grows
Large sequencing databases keep recording how often each variant appears in the general population. A change that turns up commonly in people without disease accumulates evidence toward benign.
Family co-segregation is studied
When a variant consistently travels with disease through affected relatives — or, just as informatively, appears in healthy family members — that pattern shifts the weight of evidence in one direction.
Functional and computational evidence is added
Laboratory experiments on how the variant affects protein function, plus refined computational prediction, contribute additional data points to the classification framework.
The lab reissues an updated classification
When the combined evidence crosses a threshold, the laboratory formally reclassifies the variant and notifies the ordering clinician — which is why staying reachable for amended reports matters.
How registries accelerate reclassification
Reclassification depends on data — and no single clinic sees enough patients carrying any one rare variant to resolve it quickly. This is precisely the problem the PROMPT registry (Prospective Registry Of MultiPlex Testing) was built to address. By pooling de-identified panel-testing results across multiple institutions, registries assemble the population frequency, family history, and outcome data that a lone laboratory could never gather on its own.
When many carriers of the same uncertain variant are observed together, patterns emerge that turn an unresolved VUS into a confident benign or pathogenic call faster. Shared, longitudinal data is the engine of reclassification — every contributed result helps refine the answer not only for that patient, but for everyone who carries the same change.
Frequently asked questions
Does a VUS mean I have a higher cancer risk?
Not by itself. A variant of uncertain significance is an unresolved finding, not evidence of elevated risk. Your risk is assessed from variants that are confidently classified as pathogenic, combined with your personal and family history — not from an uncertain result.
Should my treatment or screening change because of a VUS?
Generally no. Professional guidelines recommend that medical management not be based on a VUS. Most clinicians continue the screening plan that fits your family history and wait for the variant to be reclassified rather than acting on the uncertain finding.
Will my VUS ever get a clearer answer?
Often, yes. Classifications are revisited as data accumulates, and the majority of uncertain variants are eventually reclassified — most commonly as benign. Reclassification can take months to years, depending on how rare the variant is and how quickly relevant evidence is gathered.
How will I find out if my variant is reclassified?
Laboratories typically issue an amended report to the clinician who ordered the test when a classification changes. Keeping your contact information and that of your genetic counselor current ensures you are notified if an update is released.
Should relatives get tested for my VUS?
Cascade testing for an uncertain variant is usually not recommended, because the result cannot guide management. Testing decisions for relatives are generally based on confidently classified variants and on the family's cancer history, a conversation best had with a genetic counselor.
Uncertain is not the same as alarming
A variant of uncertain significance is a normal, expected part of comprehensive genetic testing — and one of the most resolvable. If you have questions about a result or want plain-language reference material on hereditary cancer genetics, we're glad to point you to the right explanation.